+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial



Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial



Cornea 32(10): 1297-1304



Supplementation with gamma-linolenic acid (GLA) and omega-3 (n-3) polyunsaturated fatty acids (PUFAs) has been found to decrease the production of disease-relevant inflammatory mediators that are implicated in the pathogenesis of chronic dry eye. This study evaluated the effect of a supplement containing both GLA and n-3 PUFAs on signs and symptoms of moderate-to-severe keratoconjunctivitis sicca in postmenopausal patients. This multicenter, double-masked placebo-controlled clinical trial enrolled 38 patients (both eyes) with tear dysfunction who were randomized to supplemental GLA + n-3 PUFAs or placebo for 6 months. Disease parameters, including Ocular Surface Disease Index, Schirmer test, tear breakup time, conjunctival fluorescein and lissamine green staining, and topographic corneal smoothness indexes (surface asymmetry index and surface regularity index), were assessed at baseline and at 4, 12, and 24 weeks. The intensity of dendritic cell CD11c integrin and HLA-DR expression was measured in conjunctival impression cytologies. The Ocular Surface Disease Index score improved with supplementation and was significantly lower than placebo (21 ± 4 vs. 34 ± 5) after 24 weeks (P = 0.05, n = 19 per group). The surface asymmetry index was significantly lower in supplement-treated subjects (0.37 ± 0.03, n = 15) than placebo (0.51 ± 0.03, n = 16) at 24 weeks (P = 0.005). Placebo treatment also significantly increased HLA-DR intensity by 36% ± 9% and CD11c by 34% ± 7% when compared with supplement treatment (n = 19 per group, P = 0.001, 24 weeks). Neither treatment had any effect on tear production, tear breakup time, or corneal or conjunctival staining. Supplemental GLA and n-3 PUFAs for 6 months improved ocular irritation symptoms, maintained corneal surface smoothness, and inhibited conjunctival dendritic cell maturation in patients with postmenopausal keratoconjunctivitis sicca.Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00883649.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054161422

Download citation: RISBibTeXText

PMID: 23884332

DOI: 10.1097/ico.0b013e318299549c


Related references

0.25 percent bendazac lysine eye drops efficacy in keratoconjunctivitis sicca a double blind randomized clinical cytological trial. Bollettino di Oculistica 70(3): 541-546, 1991

Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial. American Journal of Clinical Nutrition 103(5): 1260-1266, 2016

Randomized double-blind clinical trial of moderate dosage naloxone in acute moderate and severe traumatic brain injury. Hunan Yi Ke Da Xue Xue Bao 27(1): 58-60, 2002

Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. Journal of Clinical Endocrinology and Metabolism 92(9): 3446-3452, 2007

Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with moderate-to-severe dementia Results from a short-term, randomized, double-blind, placebo-controlled clinical trial. Neuropsychopharmacology 23(S2): S126, 2000

Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial. European Neuropsychopharmacology 18(11): 803-813, 2008

Continuation and long-term maintenance treatment with Hypericum extract WSReg 5570 after recovery from an acute episode of moderate depression - a double-blind, randomized, placebo controlled long-term trial. European Neuropsychopharmacology: 11, 803-813, 2008

Metronidazole gel in treatment of moderate to severe rosacea: A randomized, double-blind, placebo-controlled clinical trial. Zhongguo Xinyao yu Linchuang Zazhi 21(11): 657-660, 2002

Vitamin e supplementation, lung functions and clinical manifestations in children with moderate asthma: a randomized double blind placebo- controlled trial. Iranian Journal of Allergy Asthma and Immunology 13(2): 98-103, 2014

Therapeutic effects of oral zinc supplementation on acute watery diarrhea with moderate dehydration: a double-blind randomized clinical trial. Iranian Journal of Medical Sciences 38(2): 93-99, 2013

Isotonic versus Hypotonic Fluid Supplementation in Term Neonates with Severe Hyperbilirubinemia – A Double Blind, Randomized Controlled Trial. 2011

Isotonic versus hypotonic fluid supplementation in term neonates with severe hyperbilirubinemia - a double-blind, randomized, controlled trial. Acta Paediatrica 101(3): 236-241, 2012

Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. Journal of the European Academy of Dermatology and Venereology 28(12): 1670-1675, 2014

Randomized double blind placebo controlled clinical trial of Solanum melongena L. fruit in moderate to severe asthmatics. Journal of Medical Sciences Pakistan 4(4): 263-269, 2004

Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial. American Journal of Geriatric Psychiatry 7(4): 339-348, 1999